Coverage varies significantly by region. Spanish and German public insurance occasionally reimburse intra-articular cell therapy for grade 3–4 OA when conservative measures have failed, though prior authorisation is mandatory. US insurance (Medicare, commercial plans) rarely covers investigational cell therapy for OA outside clinical trials. UK NHS generally does not reimburse. Private insurance may cover if framed as tissue repair rather than anti-ageing. Out-of-pocket payment remains standard globally.
Knee OA cell therapy ranges from €3,500–6,500 per knee in European centres. Placental MSC intra-articular injection (€4,000–5,500) is most common. Autologous chondrocyte implantation commands premium pricing (€6,000–8,000) owing to required surgical harvest and extended culture. Exosome-based intra-articular therapies cost €3,500–5,000. Bilateral knees require separate procedures, doubling cost. Repeat injections (often recommended at 6–12 month intervals) significantly increase lifetime expenditure. Insurance selectively reimburses in some European countries (e.g., Spain, Germany) under medical necessity frameworks; US coverage is rare.
Am I a candidate? → · Knee Osteoarthritis: full overview → · Knee Osteoarthritis cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment